Brokerage firm Goldman Sachs Downgrades its rating on AstraZeneca plc (ADR)(NYSE:AZN). The shares have been rated Sell. Previously, the analysts had a Neutral rating on the shares. The rating by Goldman Sachs was issued on Apr 11, 2016.
In a different note, On Mar 15, 2016, Jefferies said it Downgrades its rating on AstraZeneca plc (ADR). The shares have been rated ‘Hold’ by the firm. Drexel Hamilton said it Initiates Coverage on AstraZeneca plc (ADR), according to a research note issued on Feb 29, 2016. The shares have been rated ‘Buy’ by the firm. Cantor Fitzgerald said it Initiates Coverage on AstraZeneca plc (ADR), according to a research note issued on Feb 26, 2016. The shares have been rated ‘Buy’ by the firm. On Feb 8, 2016, HBSC said it Downgrades its rating on AstraZeneca plc (ADR). The shares have been rated ‘Hold’ by the firm. On Jan 26, 2016, Oddo Securities said it Upgrades its rating on AstraZeneca plc (ADR). The shares have been rated ‘Top Pick’ by the firm. On Jan 19, 2016, Barclays said it Upgrades its rating on AstraZeneca plc (ADR). According to the research note, Barclays Raises the price target to $50 per share from a prior target of $44. The shares have been rated ‘Equal-weight’ by the firm.
AstraZeneca plc (ADR) (AZN) made into the market gainers list on Fridays trading session with the shares advancing 0.24% or 0.07 points. Due to strong positive momentum, the stock ended at $29.71, which is also near the day’s high of $29.8. The stock began the session at $29.74 and the volume stood at 22,67,958 shares. The 52-week high of the shares is $36.69 and the 52 week low is $27.68. The company has a current market capitalization of $75,121 M and it has 2,52,84,66,300 shares in outstanding.
AstraZeneca plc (ADR)(AZN) last announced its earnings results on Feb 4, 2016 for Fiscal Year 2015 and Q4.Company reported revenue of $6.40B. Analysts had an estimated revenue of $6.28B. Earnings per share were $0.94. Analysts had estimated an EPS of $0.88.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory inflammation and autoimmunity and infection neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia bipolar disorder and depressive disorder and Synagis for RSV (respiratory syncytial virus) a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9) a treatment for hyperkalaemia a condition associated with increased mortality in patients with chronic kidney disease (CKD) diabetes mellitus (DM) and chronic heart failure (CHF).